TMEM115: a promising marker for glioma immunotherapy and prognosis
These findings support TMEM115 as a potential independent prognostic biomarker in glioma and suggest its promise as a target for immunotherapy.
Authors
- Haiyan Xu (ORCID: https://orcid.org/0000-0002-0048-3191)
- Ping‐Ping Sun (ORCID: https://orcid.org/0000-0002-2772-2631)
- Manyu Xu (ORCID: https://orcid.org/0000-0002-5730-4334)
- Bing Lu
- Jianfei Huang (ORCID: https://orcid.org/0000-0002-1276-5962)
- Xiaojing Zhang (ORCID: https://orcid.org/0000-0001-7032-7154)
- Hang Yin
- Lei Yang (ORCID: https://orcid.org/0000-0002-9153-2664)
- Peng‐Peng Lü (ORCID: https://orcid.org/0000-0003-3949-9016)
- Feng Wang (ORCID: https://orcid.org/0009-0003-1503-545X)
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1598499
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Government of Jiangsu Province